Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for 3rd- and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer

Martin Hoyle, Jaime Peters, Louise Crathorne, Tracey Jones-Hughes, Chris Cooper, Mark Napier, Chris Hyde

Research output: Contribution to journalArticle

24 Citations (Scopus)

Fingerprint Dive into the research topics of 'Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for 3rd- and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences